Development of novel therapies for Huntington's disease:hope and challenge  

作　　者：Zheng-hongQIN JinWANG Zhen-lunGU 

机构地区：[1]DepartmentofPharmacology,SoochowUniversitySchoolofMedicine,Suzhou215007,China//LaboratoryofCellularNeurobiology,MassachusettsGeneralHospitalandHarvardMedicalSchool,Charlestown,MA02129,USA// [2]MolecularNeurogeneticsUnit,CenterforHumanGeneticsResearch,MassachusettsGeneralHospitalandHarvardMedicalSchool,Charlestown,MA02129,USA [3]DepartmentofPharmacology,SoochowUniversitySchoolofMedicine,Suzhou215007,China

出　　处：《Acta Pharmacologica Sinica》2005年第2期129-142,共14页中国药理学报（英文版）

基　　金：Supported by the National Natural Science Foundation of China(№ 30370506).

摘　　要：Huntington's disease(HD)is an autosomal dominant neurological disease.It is a fatal neurological disorder affecting 5-10 out of 10000 people.While there are intensive research efforts focusing on uncovering molecular mechanisms of the pathogenesis of HD,a number of studies have begun to look for effective thera- pies for HD.There is a large body of encouraging news on novel therapeutic developments.The present paper reviews drugs used for symptomatic treatment of HD and experimental therapies targeting HD molecular pathology.Huntington's disease(HD)is an autosomal dominant neurological disease.It is a fatal neurological disorder affecting 5-10 out of 10000 people.While there are intensive research efforts focusing on uncovering molecular mechanisms of the pathogenesis of HD,a number of studies have begun to look for effective thera- pies for HD.There is a large body of encouraging news on novel therapeutic developments.The present paper reviews drugs used for symptomatic treatment of HD and experimental therapies targeting HD molecular pathology.

关 键 词：Huntington disease HUNTINGTIN AGGREGATES CASPASES nerve growth factors cell transplantation coenzyme Q10 

分 类 号：R742[医药卫生—神经病学与精神病学] R97[医药卫生—临床医学]